Estimating Global Friction Periods for Economic Evaluation: A Case Study of Selected OECD Member Countries.


Journal

PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404

Informations de publication

Date de publication:
09 2023
Historique:
accepted: 05 03 2023
medline: 28 8 2023
pubmed: 11 4 2023
entrez: 10 4 2023
Statut: ppublish

Résumé

The friction cost approach (FCA) offers an alternative to the dominant human capital approach to value productivity losses. Application of the FCA in practice is limited largely due to data availability. Recent attempts have tried to standardise the estimation of friction periods across Europe, but to date, this has not been attempted elsewhere. Our aim was to estimate friction periods for 17 Organisation for Economic Co-operation and Development (OECD) member countries between 2010 and 2021 based on routinely published data. We derived friction period estimates for Australia, Austria, Canada, Czechia, Finland, Germany, Hungary, Japan, Korea, Luxembourg, Norway, Poland, Portugal, Sweden, Switzerland, the United Kingdom and the United States. Vacancy stock and flow data was sourced from the OECD's short-term labour situation database from 2010 to 2021, and included the impact of Covid-19 on the labour market. The estimated friction periods were applied to cost cancer-related premature mortality for the United States as an illustrative case. The average friction period in the five non-European countries (Australia, Canada, Korea, Japan and the United States) was 61.0 days (SD 9.4) (range between 44.8 days in Korea and 82.2 days in Canada) and the average friction period in the 12 European countries was 60.6 days (SD 14.8) (range between 34.1 days in Switzerland and 137.3 days in Czechia). In both cases, the outbreak of Covid-19 increased the length of the friction period. Our illustrative case revealed that productivity costs in the US were over a third lower using the study-specific friction period (56 days) compared with the conventionally assumed 90-day friction period applied in the literature as a default measure. Our results expand the potential application of the FCA outside of Europe and will support greater utilisation of the FCA and wider inclusion of productivity costs in societal-based economic evaluations based on the use of widely available and updated key labour market variables in our selected countries.

Sections du résumé

BACKGROUND
The friction cost approach (FCA) offers an alternative to the dominant human capital approach to value productivity losses. Application of the FCA in practice is limited largely due to data availability. Recent attempts have tried to standardise the estimation of friction periods across Europe, but to date, this has not been attempted elsewhere. Our aim was to estimate friction periods for 17 Organisation for Economic Co-operation and Development (OECD) member countries between 2010 and 2021 based on routinely published data.
METHODS
We derived friction period estimates for Australia, Austria, Canada, Czechia, Finland, Germany, Hungary, Japan, Korea, Luxembourg, Norway, Poland, Portugal, Sweden, Switzerland, the United Kingdom and the United States. Vacancy stock and flow data was sourced from the OECD's short-term labour situation database from 2010 to 2021, and included the impact of Covid-19 on the labour market. The estimated friction periods were applied to cost cancer-related premature mortality for the United States as an illustrative case.
RESULTS
The average friction period in the five non-European countries (Australia, Canada, Korea, Japan and the United States) was 61.0 days (SD 9.4) (range between 44.8 days in Korea and 82.2 days in Canada) and the average friction period in the 12 European countries was 60.6 days (SD 14.8) (range between 34.1 days in Switzerland and 137.3 days in Czechia). In both cases, the outbreak of Covid-19 increased the length of the friction period. Our illustrative case revealed that productivity costs in the US were over a third lower using the study-specific friction period (56 days) compared with the conventionally assumed 90-day friction period applied in the literature as a default measure.
CONCLUSIONS
Our results expand the potential application of the FCA outside of Europe and will support greater utilisation of the FCA and wider inclusion of productivity costs in societal-based economic evaluations based on the use of widely available and updated key labour market variables in our selected countries.

Identifiants

pubmed: 37036642
doi: 10.1007/s40273-023-01261-y
pii: 10.1007/s40273-023-01261-y
pmc: PMC10088804
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1093-1101

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Références

Targoutzidis A. Some adjustments to the human capital and the friction cost methods. Eur J Health Econ. 2018;19(9):1225–8.
doi: 10.1007/s10198-018-0969-z pubmed: 29564606
Krol M, Papenburg J, Koopmanschap M, Brouwer W. Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. PharmacoEcon. 2011;29(7):601–19.
doi: 10.2165/11539970-000000000-00000
Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics. 2013;31(7):537–49.
doi: 10.1007/s40273-013-0056-3 pubmed: 23620213
Kigozi J, Jowett S, Lewis M, Barton P, Coast J. Estimating productivity costs using the friction cost approach in practice: a systematic review. Eur J Health Econ. 2016;17(1):31–44.
doi: 10.1007/s10198-014-0652-y pubmed: 25387561
Hanly P, Ortega-Ortega M, Sharp L. Friction costs and the chain of vacancies problem: a novel vacancy multiplier solution. Value Health. 2021;24(4):548–55. https://doi.org/10.1016/j.jval.2020.10.026 .
doi: 10.1016/j.jval.2020.10.026 pubmed: 33840433
Hanly P, Ortega Ortega M, Pearce A, Soerjomataram I, Sharp L. Advances in the methodological approach to friction period estimation: a European perspective. Soc Sci Med. 2020;264: 113289. https://doi.org/10.1016/j.socscimed.2020.113289 .
doi: 10.1016/j.socscimed.2020.113289 pubmed: 32836019
Hanly P, Koopmanschap M, Sharp L. Valuing productivity costs in a changing macroeconomic environment: the estimation of colorectal cancer productivity costs using the friction cost approach. Eur J Health Econ. 2016;17(5):553–61. https://doi.org/10.1007/s10198-015-0698-5 .
doi: 10.1007/s10198-015-0698-5 pubmed: 26022915
Kigozi J, Jowett S, Lewis M, Barton P, Coast J. Valuing productivity costs using the friction-cost approach: estimating friction-period estimates by occupational classifications for the UK. Health Econ. 2017;26(12):1862–8. https://doi.org/10.1002/hec.3513 .
doi: 10.1002/hec.3513 pubmed: 28449329
Pike J, Grosse SD. Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: a review. Appl Health Econ Health Policy. 2018;16(6):765–78.
doi: 10.1007/s40258-018-0416-4 pubmed: 30094591 pmcid: 6467569
Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics. 2014;32(4):335–44.
doi: 10.1007/s40273-014-0132-3 pubmed: 24504850
Hanly P, Ortega-Ortega M, Soerjomataram I. Cancer premature mortality costs in Europe in 2020: a comparison of the human capital approach and the friction cost approach. Curr Oncol. 2022;29(5):3552–64. https://doi.org/10.3390/curroncol29050287 .
doi: 10.3390/curroncol29050287 pubmed: 35621677 pmcid: 9139545
Ando S, Balakrishnan R, Gruss B, Hallaert J-J, Jirasavetakul LB F, Kirabaeva K, Klein N, Lariau A, Liu LQ, Malacrino D, Qu H, Solovyeva A. European labor markets and the Covid-19 pandemic: fallout and the path ahead, Departmental Paper No. DP/2022/004, IMF; 2022.
International Labour Organization. Job retention schemes during COVID-19: a review of policy responses; 2022.
Nyman J. Productivity costs revisited: toward a new US policy. Health Econ. 2012;21:1387–401. https://doi.org/10.1002/hec.1795 .
doi: 10.1002/hec.1795
Yuasa A, Yonemoto N, Kamei K, Murofushi T, LoPresti M, Taneja A, Horgan J, Ikeda S. Systematic literature review of the use of productivity losses/gains in cost-effectiveness analyses of immune-mediated disorders. Adv Ther. 2022;39(12):5327–50.
doi: 10.1007/s12325-022-02321-z pubmed: 36205907 pmcid: 9540264
Hanly P, Timmons A, Walsh PM, Sharp L. Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach. Value Health. 2012;15(3):429–36.
doi: 10.1016/j.jval.2011.12.012 pubmed: 22583452
International Monetary Fund (IMF) World Economic outlook Update: Inflation Peaking Amid Low Growth, 2023. https://www.imf.org/en/Publications/WEO/Issues/2023/01/31/world-economic-outlook-update-january-2023 . Accessed 20 Feb 2023.

Auteurs

Paul Hanly (P)

School of Business, National College of Ireland, Mayor Street, Dublin 1, Ireland. paul.hanly@ncirl.ie.

Marta Ortega Ortega (M)

Department of Applied and Public Economics, and Political Economy, Faculty of Economics and Business, Complutense University of Madrid, Campus de Somosaguas, Pozuelo de Alarcón, 28223, Madrid, Spain.

Alison Pearce (A)

Sydney School of Public Health, The University of Sydney, Sydney, NSW, 2006, Australia.

Marianna de Camargo Cancela (M)

Division of Cancer Surveillance and Data Analysis, Brazilian National Cancer Institute, Ministry of Health, Rua Marquês de Pombal 125, Rio de Janeiro, 22230-24, Brazil.

Isabelle Soerjomataram (I)

International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon Cedex 08, France.

Linda Sharp (L)

Population Health Sciences Institute, Newcastle University Centre for Cancer, Sir James Spence Institute, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH